Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
about
Tuberculosis vaccines and prevention of infectionCrosstalk between Mycobacterium tuberculosis and the host cellA New Rabbit-Skin Model to Evaluate Protective Efficacy of Tuberculosis Vaccines.Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.Mast Cells in Lung Homeostasis: Beyond Type I HypersensitivityKinetics of IFN-gamma and TNF-alpha gene expression and their relationship with disease progression after infection with Mycobacterium tuberculosis in guinea pigs.CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.A spotlight on liquefaction: evidence from clinical settings and experimental models in tuberculosis.Tuberculosis vaccines in clinical trials.Animal models in tuberculosis research - where is the beef?Subunit Vaccines Consisting of Antigens from Dormant and Replicating Bacteria Show Promising Therapeutic Effect against Mycobacterium Bovis BCG Latent Infection.Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical Testing, and III. Clinical Testing.Tuberculosis vaccines: Opportunities and challenges.Fc-based delivery system enhances immunogenicity of a tuberculosis subunit vaccine candidate consisting of the ESAT-6:CFP-10 complex.The wide utility of rabbits as models of human diseases.
P2860
Q26782022-8E19CDA3-240F-4490-A606-44D5D8AAF4E0Q27022090-6C25CE7F-E146-4A3A-BB15-9BF61B2B01AFQ33697290-C7AFB187-ACE7-45D8-A215-C20BA2CC1EEBQ34260720-0ECC0A3D-BE0B-4F52-9ECE-127D2D364118Q34628122-BBDA125A-EDA8-4CF2-B86D-5B87F1669B1CQ36793138-3D1B00FC-D15D-4211-9714-A7A2E87659B4Q36811028-50C36210-284D-457F-A8D8-B6FA518B60B7Q36934339-25DD1EC2-7650-45BA-8066-545BFE696CF6Q37857711-2E011AE2-6CF1-4718-BF39-1B9AAC566BDFQ37878483-150BDC0C-1497-49A6-8C8C-498692BB5662Q38527417-A74F1D13-323B-45ED-B5C9-3FD091CB01D5Q39251983-6F56124E-229A-466C-B6CD-2C7B1F27D9E3Q40568831-2C87FA8C-F48B-4B35-A672-C2C8BF13D12DQ47552546-177994FB-66BE-41D6-948A-54153444160AQ51347966-87B6F663-D506-42BF-9748-87BE08EDE807Q55250836-6D403A51-D773-4B23-8E71-0C796C7A065B
P2860
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@ast
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@en
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@nl
type
label
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@ast
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@en
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@nl
prefLabel
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@ast
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@en
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@nl
P2860
P356
P1476
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
@en
P2093
Arthur M Dannenberg
P2860
P304
P356
10.1128/CMR.00005-10
P407
P577
2010-10-01T00:00:00Z